4 ms·
New drug multiplies survival rate for women with breast cancer
- belter 5y ago"...An international study has found that patients given trastuzumab deruxtecan had an estimated overall survival rate of 94% after 12 months..." "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer": https://www.nejm.org/doi/full/10.1056/nejmoa1914510 https://www.nejm.org/doi/full/10.1056/nejmoa1914510